MedCity News
MAY 19, 2024
Carter entered hospice care in his home, more than a year ago, and has set an inspirational example of how to live your last days on Earth with hope, meaning, and vigor. The post The Powerful Hospice Lessons of Jimmy Carter appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
Discover what industry professionals seek in contract manufacturing for parenteral solutions. Ensure quality, compliance, and innovation with our comprehensive guide. Click to learn more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
MAY 19, 2024
Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement. The post ‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care appeared first on MedCity News.
Pharmacy Times
MAY 19, 2024
Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
MAY 19, 2024
How employers are optimizing weight-loss medication cost and coverage The post Balancing Weight-loss Medication Cost and Care appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
PLX-038 is under clinical development by ProLynx and currently in Phase II for Ependymoma.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
MAY 19, 2024
PLX-038 is under clinical development by ProLynx and currently in Phase II for Recurrent Medulloblastoma.
MedCity News
MAY 19, 2024
Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder. The post CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
Dipraglurant is under clinical development by Addex Therapeutics and currently in Phase II for Blepharospasm.
Pharmaceutical Technology
MAY 19, 2024
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Melanoma.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
MAY 19, 2024
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma.
Pharmaceutical Technology
MAY 19, 2024
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma.
Pharmaceutical Technology
MAY 19, 2024
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma).
Pharmaceutical Technology
MAY 19, 2024
Elixcyte is under clinical development by Unicocell Biomed and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure).
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
MAY 19, 2024
Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
Pharmaceutical Technology
MAY 19, 2024
Furmonertinib mesylate is under clinical development by Shanghai Allist Pharmaceuticals and currently in Phase II for Lung Adenocarcinoma.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Malignant Mesothelioma.
Pharmaceutical Technology
MAY 19, 2024
SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.
Expert insights. Personalized for you.
128 
Let's personalize your content